N-acetylcysteine administration confers lung protection in different phases of lung ischaemia-reperfusion injury

Interact Cardiovasc Thorac Surg. 2014 Dec;19(6):894-9. doi: 10.1093/icvts/ivu258. Epub 2014 Aug 24.

Abstract

Objectives: To verify the effects of N-acetylcysteine (NAC) administered before and after ischaemia in an animal model of lung ischaemia-reperfusion (IR) injury.

Methods: Twenty-four Wistar rats were subjected to an experimental model of selective left pulmonary hilar clamping for 45 min followed by 2 h of reperfusion. The animals were divided into four groups: control group (SHAM), ischaemia-reperfusion, N-acetylcysteine-preischaemia (NAC-Pre) and NAC-postischaemia (NAC-Post). We recorded the haemodynamic parameters, blood gas analysis and histology. We measured the thiobarbituric acid reactive substances concentration; the expression of superoxide dismutase (SOD), inducible nitric oxide synthase (iNOS), nitrotyrosine, cleaved caspase 3, nuclear factor κB (NF-κB), NF-kappa-B inhibitor alpha (IκB-α), tumour necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β); myeloperoxidase activity (MPO).

Results: No significant differences were observed in the haemodynamic parameters, blood gas analysis and SOD activity among the groups. Lipid peroxidation was significantly higher in the IR and NAC-Pre groups (P < 0.01). The expression of nitrotyrosine, cleaved caspase 3, NF-κB, IκB-α, TNF-α and IL-1β were significantly higher in the IR group when compared with the SHAM and NAC groups (P < 0.01). The NAC-Pre group showed a significantly higher expression of these proteins when compared with the SHAM and NAC-Post groups (P < 0.05). After reperfusion, the expression of iNOS increased almost uniformly in all groups when compared with the SHAM group (P < 0.01). The histological analysis showed fewer inflammatory cells in the NAC groups.

Conclusions: The intravenous administration of NAC demonstrated protective properties against lung IR injury. The use of NAC immediately after reperfusion potentiates its protective effects.

Keywords: Inflammation; Ischaemia–reperfusion; N-Acetylcysteine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / administration & dosage*
  • Administration, Intravenous
  • Animals
  • Anti-Inflammatory Agents / administration & dosage*
  • Antioxidants / administration & dosage*
  • Caspase 3 / metabolism
  • Cytoprotection
  • Disease Models, Animal
  • Hemodynamics / drug effects
  • I-kappa B Kinase / metabolism
  • Inflammation Mediators / metabolism
  • Interleukin-1beta / metabolism
  • Lipid Peroxidation / drug effects
  • Lung / blood supply*
  • Lung / drug effects*
  • Lung / metabolism
  • Lung / pathology
  • Lung Injury / metabolism
  • Lung Injury / pathology
  • Lung Injury / physiopathology
  • Lung Injury / prevention & control*
  • NF-kappa B / metabolism
  • Nitric Oxide Synthase Type II / metabolism
  • Oxidative Stress / drug effects
  • Peroxidase / metabolism
  • Rats, Wistar
  • Reperfusion Injury / metabolism
  • Reperfusion Injury / pathology
  • Reperfusion Injury / physiopathology
  • Reperfusion Injury / prevention & control*
  • Superoxide Dismutase / metabolism
  • Time Factors
  • Tumor Necrosis Factor-alpha / metabolism
  • Tyrosine / analogs & derivatives
  • Tyrosine / metabolism

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • IL1B protein, rat
  • Inflammation Mediators
  • Interleukin-1beta
  • NF-kappa B
  • Tumor Necrosis Factor-alpha
  • 3-nitrotyrosine
  • Tyrosine
  • Peroxidase
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat
  • Superoxide Dismutase
  • I-kappa B Kinase
  • Casp3 protein, rat
  • Caspase 3
  • Acetylcysteine